Elanco Perspective: China Ministry of Commerce’s Announcement Regarding Ractopamine

Greenfield, Indiana – Elanco, the global manufacturer and marketer of Paylean® for swine and Optaflexx® for cattle (ractopamine hydrochloride), said today that it welcomed China's ban on the export of ractopamine and ractopamine hydrochloride products from China as a step that will help eliminate the production and use for food animals of ”black and grey market” versions of ractopamine in China and other parts of the world.

Dennis Erpelding, Elanco’s director of corporate affairs for China and International Trade, stated, “Only Elanco’s branded Paylean and Optaflexx products have gone through the stringent human safety assessment procedures by the United States and 25 other regulatory authorities around the world and been determined as safe for use in food animals. Further, only Elanco’s branded product has been assessed through the global Codex standards establishment body.

"Elanco’s branded ractopamine hydrochloride products, Paylean and Optaflexx, are not approved, available or sold within China, and thus any such product used within China is different from Elanco’s. We are pleased to support the China government in their efforts to ensure the safe use of well-tested, well-regulated products and eliminate those ‘grey and black market’ products that potentially pose a food safety risk to consumers. The production of a safe, abundant and sustainable food supply is a shared interest of the China government and Elanco," said Erpelding.

Erpelding noted, "We are in regular contact with Chinese officials to discuss how our safe, branded products can help overcome the daunting challenge of providing sufficient safe food through a secure supply chain for China's rapidly-growing population.”

About Elanco

Elanco is a global innovation-driven company that develops and markets products to improve animal health and food animal production in more than 75 countries. Elanco employs 2,300 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a leading global pharmaceutical corporation. Additional information about Elanco is available at